UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 71

Sortiert nach

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

PloS one, 2016-02, Vol.11 (2), p.e0149099

2016

Volltextzugriff (PDF)

A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds

PLoS genetics, 2017-08, Vol.13 (8), p.e1006942

2017

Volltextzugriff (PDF)

Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition

Molecular biology of the cell, 2015-09, Vol.26 (17), p.2971-2985

2015

Volltextzugriff (PDF)

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS

Cell chemical biology, 2017-08, Vol.24 (8), p.1017-1028.e7

2017

Volltextzugriff (PDF)

Target identification for small-molecule discovery in the FOXO3a tumor-suppressor pathway using a biodiverse peptide library

Cell chemical biology, 2021-11, Vol.28 (11), p.1602-1615.e9

2021

Volltextzugriff (PDF)

Use of isogenic human cancer cells for high-throughput screening and drug discovery

Nature biotechnology, 2001-10, Vol.19 (10), p.940-945

2001

Volltextzugriff (PDF)

Combinatorial chemoprevention of intestinal neoplasia

Nature medicine, 2000-09, Vol.6 (9), p.1024-1028

2000

Volltextzugriff (PDF)

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

PloS one, 2018-10, Vol.13 (10), p.e0206729-e0206729

2018

Volltextzugriff (PDF)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

PloS one, 2017-04, Vol.12 (4), p.e0176578-e0176578

2017

Volltextzugriff (PDF)

Cancer cell senescence: a new frontier in drug development

Drug discovery today, 2012-03, Vol.17 (5-6), p.269-276

2012

Volltextzugriff (PDF)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

PloS one, 2016-04, Vol.11 (4), p.e0154007-e0154007

2016

Volltextzugriff (PDF)

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

PloS one, 2012-05, Vol.7 (5), p.e36402-e36402

2012

Volltextzugriff (PDF)

Simple and precise targeted editing of the human genome using rAAV-mediated homologous recombination

BMC proceedings, 2012-10, Vol.6 (S6), p.P51-P51, Article P51

Torrance, Christopher J

2012

Volltextzugriff (PDF)

DEC1 is a Downstream Target of TGF-β with Sequence-Specific Transcriptional Repressor Activities

Proceedings of the National Academy of Sciences - PNAS, 2002-03, Vol.99 (5), p.2848-2853

2002

Volltextzugriff (PDF)

Triazolo[1,5- a]pyrimidines as novel CDK2 inhibitors: Protein structure-guided design and SAR

Bioorganic & medicinal chemistry letters, 2006-03, Vol.16 (5), p.1353-1357

2006

Volltextzugriff (PDF)

Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping

Bioorganic & medicinal chemistry letters, 2007-07, Vol.17 (14), p.3880-3885

2007

Volltextzugriff (PDF)

Structure-guided design of pyrazolo[1,5- a]pyrimidines as inhibitors of human cyclin-dependent kinase 2

Bioorganic & medicinal chemistry letters, 2005-02, Vol.15 (4), p.863-867

2005

Volltextzugriff (PDF)

Effects of Thyroid Hormone on GLUT4 Glucose Transporter Gene Expression and NIDDM in Rats

Endocrinology (Philadelphia), 1997-03, Vol.138 (3), p.1204-1214

1997

Volltextzugriff (PDF)

The Relationship Between Technological Self-Efficacy and Organizational Citizenship Behavior During Covid-19: Analyzing the Moderating Role of Trust

The journal of applied business and economics, 2023-12, Vol.25 (5)

2023

Volltextzugriff (PDF)

Emergency Management Agents Value Assessment of Public Private Partnerships

International management review, 2021-04, Vol.17 (2), p.5-145

2021

Volltextzugriff (PDF)

Characterization of a Low Affinity Thyroid Hormone Receptor Binding Site within the Rat GLUT4 Gene Promoter

Endocrinology (Philadelphia), 1997-03, Vol.138 (3), p.1215-1223

1997

Volltextzugriff (PDF)

Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model

BMC research notes, 2014-06, Vol.7 (1), p.397-397, Article 397

2014

Volltextzugriff (PDF)

Abstract A148: Modeling patient responses to targeted therapy with rAAV mediated gene editing

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.A148-A148

2013

Volltextzugriff (PDF)

Abstract A33: Metastasis score expression profiling of isogenic cell lines with defined oncogenic mutations and upon treatment with an inhibitor of PI3K/PTEN signaling pathway

Clinical cancer research, 2010-07, Vol.16 (14_Supplement), p.A33-A33

2010

Volltextzugriff (PDF)

Abstract 5145: Glycolytic gene expression in ER-positive breast cancer tumors: Comparison with metastasis scores

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.5145-5145

2012

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(66)

Publikationsform

Sprache

Englisch
(71)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(35)
Humans
(31)
Female
(18)
Male
(13)
Animals
(12)
Biological And Medical Sciences
(9)
Middle Aged
(8)
Tumors
(8)
Gastroenterology & Hepatology
(7)
Mice
(7)
Cancer
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
K-Ras Protein
(6)
Medical Research
(6)
Pharmacology & Pharmacy
(6)
Adult
(5)
Analysis
(5)
Biochemistry & Molecular Biology
(5)
Cell Line, Tumor
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds

Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS

Target identification for small-molecule discovery in the FOXO3a tumor-suppressor pathway using a biodiverse peptide library

Use of isogenic human cancer cells for high-throughput screening and drug discovery

Combinatorial chemoprevention of intestinal neoplasia

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Cancer cell senescence: a new frontier in drug development

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

Simple and precise targeted editing of the human genome using rAAV-mediated homologous recombination

DEC1 is a Downstream Target of TGF-β with Sequence-Specific Transcriptional Repressor Activities

Triazolo[1,5- a]pyrimidines as novel CDK2 inhibitors: Protein structure-guided design and SAR

Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping

Structure-guided design of pyrazolo[1,5- a]pyrimidines as inhibitors of human cyclin-dependent kinase 2

Effects of Thyroid Hormone on GLUT4 Glucose Transporter Gene Expression and NIDDM in Rats

The Relationship Between Technological Self-Efficacy and Organizational Citizenship Behavior During Covid-19: Analyzing the Moderating Role of Trust

Emergency Management Agents Value Assessment of Public Private Partnerships

Characterization of a Low Affinity Thyroid Hormone Receptor Binding Site within the Rat GLUT4 Gene Promoter

Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model

Abstract A148: Modeling patient responses to targeted therapy with rAAV mediated gene editing

Abstract A33: Metastasis score expression profiling of isogenic cell lines with defined oncogenic mutations and upon treatment with an inhibitor of PI3K/PTEN signaling pathway

Abstract 5145: Glycolytic gene expression in ER-positive breast cancer tumors: Comparison with metastasis scores

Suchergebnisse filtern